Prostaglandins epoprostenol

Prostaglandin EJ (Prostin VR) Epoprostenol (Rolan) Fenoldopam (Corlopam) Hydralazine... 

Common Name Epoprostenol sodium Prostaglandin I2 Prostaglandin X Structural Formula ... 

Its main use is in extracorporeal procedures, such as kidney dialysis. It has a very short lifetime in the body, though it can be given by continuous infusion in vivo. epoprostenol sodium epoprostenol. epOStane [ban. inn, usan] (Win 32729) is a synthetic prostaglandin carbonitrile derivative antiprogestogen, which has been investigated for use as an abortifacient and OXYTOCIC AGENT, and to induce labour. gppyTM M adrenaline. 

Epoprostenol (Prostaglandin I, Prostacyclin). Epoprostenol is the name used to describe a prostacyclin formulation for exogenous administration. This drug has a very short half-life in the body and is rapidly broken down to 6-keto-PGF . Prostacyclin is a vasodilator and potent inhibitor of platelet aggregation and is used to treat pulmonary hy-... 

Epoprostenol has also been used in patients with ischemic stroke. However, the pathophysiological involvement of endogenous prostaglandins in ischemic brain damage is not clear, and no studies showing significant, sustained therapeutic benefits with epoprostenol have been reported (321,322). 

Answer A. During fetal development, the ductus arteriosus is kept open by prostaglandins. For temporary maintenance of patency in the infant, the PGE1 analog alprostadil is used. Closure of the ductus in the infant can often be accomplished by IV indomethacin, which decreases PG synthesis by inhibiting COX. Epoprostenol is a prostacyclin analog used in primary pulmonary HTN. 

PGlj prostaglandin vasodilator and inhibitor of platelet aggregation. An analog, epoprostenol, is used in primary pulmonary HTN. 

Epoprostenol sodium (prostacyclin) is a naturally occurring prostaglandin indicated for the preservation of platelet function during cardiopvdmonary bypass, prevention of platelet aggregation during charcoal hemoperfusion of patients in hepatic failure, euid as an alternative to heparin during rened dialysis. 

Limited evidence su ests that the combined use of intravenous high-dose epoprostenol and warfarin may increase the risk of pulmonary haemorrhage. Continuous subcutaneous treprostinil did not alter the pharmacokinetics or the INR in response to singledose warfarin, and also did not appear to increase the risk of bleeding when used with warfarin in clinical studies. Because these prostaglandins inhibit platelet a regation, some caution is appropriate on combined use with anticoagulants. 

---